Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy

Area of Science:

• Molecular Biology
• Bioengineering
• Cancer Therapeutics

Background:

• Biologic noncoding RNAs (ncRNAs) are valuable for research and therapy but challenging to produce.
• Existing methods yield low amounts or have low success rates for producing intracellular ncRNAs.
• A need exists for efficient and scalable methods to generate functional ncRNAs.

Purpose of the Study:

• To develop a novel bioengineering technology for high-yield production of recombinant ncRNAs.
• To demonstrate the selective delivery and functional activity of engineered ncRNAs in human cells and animal models.
• To evaluate the therapeutic potential of bioengineered ncRNAs in lung cancer.

Main Methods:

• Development of a stable ncRNA carrier (nCAR) for enhanced expression of pre-miRNA derivatives.
• Optimization of bacterial expression systems for high-level production (40%-80% of total RNAs) and purification methods (FPLC, spin-column).
• In vitro and in vivo studies using engineered nCAR/miRNAs to assess cellular uptake, target gene regulation, and anti-cancer efficacy in lung carcinoma models.

Main Results:

• Achieved an 80% success rate in producing 33 diverse ncRNAs using the nCAR system.
• Demonstrated selective and Dicer-dependent or -independent release of miRNAs into human cells, altering miRNome and transcriptome profiles.
• Showcased significant suppression of human lung carcinoma cell proliferation and metastatic lung xenograft progression in vivo.

Conclusions:

• The novel ncRNA bioengineering platform offers a robust and scalable method for producing functional biologic ncRNAs.
• Engineered ncRNAs exhibit specific gene regulation and potent anti-cancer activity, targeting key pathways in lung cancer.
• Bioengineered ncRNAs represent a promising new class of therapeutics for cancer treatment.